Discover how governance, process standardization, and digital technology transform QMS harmonization into a scalable enterprise capability.
USP <665> goes live in 2026. Are your polymer components compliant? Learn why early risk assessment is the key—and how to prepare.
Read how FDA’s new CSA guidance simplifies software assurance with a risk-based, least-burdensome approach.
Scaling globally? Discover why harmonization is a strategic necessity, not a choice.
AI is transforming pharmacovigilance. Learn why strong human oversight remains essential to ensure patient safety and regulatory compliance.
Introducing AI requires more than technology. Learn how to secure organizational support, and build a foundation for compliant AI adoption.
Digitalization and new regulations are transforming C&Q, driving a shift toward risk‑based, data‑driven, and fully digital validation practices.
ICH M14 provides a global framework for non‑interventional studies using real‑world data, enhancing transparency, consistency, and methodological.
ICH E6(R3) Annex 2 draft reshapes GCP for decentralized and real-world data–driven trials.
EU GMP Annex 15 will become mandatory for API manufacturers, strengthening requirements related to qualification, validation, and GMP process control.
.jpg)